| [1] |
HALLAN SI， OVREHUS MA， ROMUNDSTAD S， et al. Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway[J]. Kidney Int， 2016， 90(3): 665-673.〖ZK)〗
|
| [2] |
DECLVES AE， SHARMA K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD[J]. Nat Rev Nephrol， 2014， 10(5): 257-267.〖ZK)〗
|
| [3] |
SZETO HH. Pharmacologic approaches to improve mitochondrial function in AKI and CKD[J]. J Am Soc Nephrol， 2017， 28(10): 2856-2865.〖ZK)〗
|
| [4] |
WANG HW， SHI L， XU YP， et al. Hesperetin alleviates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro[J]. Exp Ther Med， 2017， 14(4): 3713-3719.〖ZK)〗
|
| [5] |
ELLISON DH. Treatment of disorders of Sodium balance in chronic kidney disease[J]. Adv Chronic Kidney Dis， 2017， 24(5): 332-341.〖ZK)〗
|
| [6] |
邹燕勤，王钢．孟河医派临床大家邹云翔论治肾病经验[J]．江苏中医药，2016，48（6）：1-5．〖ZK)〗
|
| [7] |
王钢．谈继承发扬邹云翔老师治肾学术思想的过程和心得体会[J]．中国中西医结合肾病杂志，2015（5）：380-385．〖ZK)〗
|
| [8] |
王钢，邹燕勤，邹孚庭．一代名医邹云翔为中国中医肾病学发展作出的贡献[J]．中国中西医结合肾病杂志，2016，17（3）：192-196．〖ZK)〗
|
| [9] |
周恩超，孙伟，易岚.邹燕勤：和诚精勤于中医肾病事业[N].中国中医药报，2017-3-22（8）.〖ZK)〗
|
| [10] |
易岚．邹燕勤治疗慢性肾小球肾炎的经验[J]．江苏中医药，2015，47（12）：11-13．〖ZK)〗
|
| [11] |
朱晓雷．邹燕勤教授运用益肾健脾，和络泄浊法治疗慢性肾衰竭的理论及临床研究[D]．南京：南京中医药大学，2016．〖ZK)〗
|
| [12] |
许陵冬，王晗.龚丽娟：益肾健脾泄浊治慢性肾衰[N].中国中医药报，2015-2-9（4）.〖ZK)〗
|
| [13] |
尤永卿，许陵冬．龚丽娟教授治疗尿酸性肾病经验撷要[J]．河北中医，2016，38（4）：487．〖ZK)〗
|
| [14] |
陶兴，许陵冬，龚丽娟．龚丽娟益肾清利法治疗慢性肾炎临床研究[J]．辽宁中医杂志，2014（1）：88．〖ZK)〗
|
| [15] |
江燕，何伟明，余承惠．肾炎湿热论[J]．四川中医，2014，32（1）：53．〖ZK)〗
|
| [16] |
李华伟．余承惠辨证结合辨病分期治疗特发性膜性肾病经验[J]．贵阳中医学院学报，2017，39（5）：12．〖ZK)〗
|
| [17] |
何伟明.余承惠教授中西医结合“治肾”观点[C]//中国中西医结合学会肾脏疾病专业委员会2015年学术年会资料汇编.南宁：中国中西医结合学会肾脏疾病专业委员会，2015：2.〖ZK)〗
|
| [18] |
王俊，徐梅昌，邓旭，等．孙伟教授益肾清利活络法治疗慢性肾脏病肾性贫血[J]．吉林中医药，2017，37（3）：226．〖ZK)〗
|
| [19] |
徐秀琴．孙伟运用扶正祛邪药对治疗慢性肾脏病经验[J]．山东中医杂志，2016，35（1）：51〖ZK)〗
|
| [20] |
沙鑫，孙伟．孙伟运用泄浊解毒法治疗慢性肾脏病阐微[J]．山东中医药大学学报，2017（2）：131．〖ZK)〗
|
| [21] |
余斐，孙伟．孙伟在激素不同阶段辨证治疗肾病综合征经验[J]．中华中医药杂志，2016（2）：539．〖ZK)〗
|
| [22] |
LEE SY， KIM SI， CHOI ME. Therapeutic targets for treating fibrotic kidney diseases[J]. Transl Res， 2015， 165(4): 512-530.〖ZK)〗
|
| [23] |
ZHOU J， ZHONG J， LIN S， et al. Inhibition of PTEN activity aggravates post renal fibrosis in mice with ischemia Reperfusion-Induced acute kidney injury[J]. Cell Physiol Biochem， 2017， 43(5): 1841-1854.〖ZK)〗
|
| [24] |
YANG R， YUAN BC， MA YS， et al. The anti-inflammatory activity of licorice， a widely used Chinese herb[J]. Pharm Biol， 2017， 55(1): 5-18.〖ZK)〗
|
| [25] |
BAO J， DING R， ZOU L， et al. Forsythiae fructus inhibits B16 melanoma growth involving MAPKs/Nrf2/HO-1 mediated Anti-Oxidation and Anti-Inflammation[J]. Am J Chin Med， 2016， 44(5): 1043-1061.〖ZK)〗
|
| [26] |
YE C， YU X， ZENG J， et al. Effects of baicalein on proliferation， apoptosis， migration and invasion of Ewing's sarcoma cells[J]. Int J Oncol， 2017: 29039470.〖ZK)〗
|
| [27] |
ZHANG S， WANG D， WANG X， et al. Aqueous extract of Bai-Hu-Tang， a classical Chinese herb formula， prevents excessive immune response and liver injury induced by LPS in rabbits[J]. J Ethnopharmacol， 2013， 149(1): 321-327.〖ZK)〗
|
| [28] |
SHIMA H， SASAKI K， SUZUKI T， et al. A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways[J]. Sci Rep， 2017， 7(1): 1884.〖ZK)〗
|
| [29] |
QUIROGA B， ARROYO D， DE ARRIBA G. Present and future in the treatment of diabetic kidney disease[J]. J Diabetes Res， 2015: 801348.〖ZK)〗
|
| [30] |
OH YJ， AN JN， KIM CT， et al. Circulating tumor necrosis factorα receptors predict the outcomes of human IgA nephropathy: a prospective cohort study[J]. PLoS One， 2015， 10(7): e0132826.〖ZK)〗
|
| [31] |
YUAN JL， TAO YY， WANG QL， et al. Fuzheng huayu formula prevents rat renal interstitial fibrosis induced by HgCl2 via antioxidative stress and down-regulation of nuclear factor-kappa B activity[J]. Chin J Integr Med， 2017， 23(8): 598-604.〖ZK)〗
|
| [32] |
HALLER ST， KUMARASAMY S， FOLT DA， et al. Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria， Independent of blood pressure[J]. Kidney Int， 2017， 91(2): 365-374.〖ZK)〗
|
| [33] |
SANZ AB， RUIZ-ANDRES O， SANCHEZ-NINO MD， et al. Out of the TWEAK light: elucidating the role of Fn14 and TWEAK in acute kidney injury[J]. Semin Nephrol， 2016， 36(3): 189-198.〖ZK)〗
|
| [34] |
RUIZ-ANDRES O， SUAREZ-ALVAREZ B， SNCHEZ-RAMOS C， et al. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury[J]. Kidney Int， 2016， 89(2): 399-410.〖ZK)〗
|
| [35] |
GOMEZ IG， ROACH AM， NAKAGAWA N， et al. TWEAK-Fn14 signaling activates myofibroblasts to drive progression of fibrotic kidney disease[J]. J Am Soc Nephrol， 2016， 27(12): 3639-3652.〖ZK)〗
|
| [36] |
BIJKERK R， DE BRUIN RG， VAN SOLINGEN C， et al. Silencing of microRNA-132 reduces renal fibrosis byselectively inhibiting myofibroblast proliferation[J]. Kidney Int， 2016， 89(6): 1268-1280.〖ZK)〗
|
| [37] |
TU Y， SUN W， WAN YG， et al. Dahuang Fuzi decoction ameliorates tubular epithelial apoptosis and renal damage via inhibiting TGF-β1-JNK signaling pathway activation in vivo[J]. J Ethnopharmacol， 2014， 156: 115-124.〖ZK)〗
|
| [38] |
ZHANG H， SONG Y， LI Z， et al. Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats[J]. Am J Surg， 2016， 211(6): 1143-1152.〖ZK)〗
|
| [39] |
YANG Y， NIAN H， TANG X， et al. Effects of the combined Herba Epimedii and Fructus Ligustri Lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats[J]. J Ethnopharmacol， 2017， 201: 91-99.〖ZK)〗
|
| [40] |
ANORGA S， OVERSTREET JM， FALKE LL， et al. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype[J]. FASEB J， 2018: fj201700722R.〖ZK)〗
|
| [41] |
RAYEGO-MATEOS S， MORGADO-PASCUAL JL， RODRIGUES-DIEZ RR， et al. Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation[J]. J Pathol， 2018， 244(2): 227-241.〖ZK)〗
|
| [42] |
刘湘丹. 补肾通络方药效物质基础及基于TGF-β1/CTGF因子的作用机制研究 [D]. 长沙：湖南中医药大学，2015.〖ZK)〗
|
| [43] |
LEE SY， KIM SI， CHOI ME. Therapeutic targets for treating fibrotic kidney diseases[J]. Transl Res， 2015， 165(4): 512-530.〖ZK)〗
|
| [44] |
NAMGUNG S， YOON JJ， YOON CS， et al. Prunella vulgaris Attenuates Diabetic Renal Injury by Suppressing Glomerular Fibrosis and Inflammation[J]. Am J Chin Med， 2017， 45(3): 475-495.〖ZK)〗
|
| [45] |
WANG N， DENG Y， LIU A， et al. Novel mechanism of the Pericyte-Myofibroblast transition in renal interstitial fibrosis: core fucosylation regulation[J]. Sci Rep， 2017， 7(1): 16914.〖ZK)〗
|
| [46] |
ISHII Y， HAMASHIMA T， YAMAMOTO S， et al. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor[J]. Pathol Int， 2017， 67(5): 235-246.〖ZK)〗
|
| [47] |
OSTENDORF T， BOOR P， VAN ROEYEN CR， et al. Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis[J]. Kidney Int Suppl， 2014， 4(1): 65-69.〖ZK)〗
|
| [48] |
BAI J， GENG W， MEI Y， et al. Effect of huaier on the proliferation of mesangial cells in Anti-Thy-1 nephritis[J]. Cell Physiol Biochem， 2017， 42(6): 2441-2452.〖ZK)〗
|
| [49] |
HAN JW， SHIM DW， SHIN WY， et al. Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation[J]. Int J Mol Sci， 2015， 16(4): 8102-8109.〖ZK)〗
|
| [50] |
ZHANG CY， ZHU JY， YE Y， et al. Erhuang formula ameliorates renal damage in adenine-induced chronic renal failure rats via inhibiting inflammatory and fibrotic responses[J]. Biomed Pharmacother， 2017， 95: 520-528.〖ZK)〗
|
| [51] |
ZHOU X， SUN X， GONG X， et al. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro[J]. Int Immunopharmacol， 2017， 42: 18-24.〖ZK)〗
|
| [52] |
FALKE LL， VAN VUUREN SH， KAZAZI-HYSENI F， et al. Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres[J]. Biomaterials， 2015， 42: 151-160.〖ZK)〗
|
| [53] |
LI XY， WANG SS， HAN Z， et al. Triptolide restores autophagy to alleviate diabetic renal fibrosis through the miR-141-3p/PTEN/Akt/mTOR pathway[J]. Mol Ther Nucleic Acids， 2017， 9: 48-56.〖ZK)〗
|
| [54] |
GAO K， CHI Y， ZHANG X， et al. A novel TXNIP-based mechanism for Cx43-mediated regulation of oxidative drug injury[J]. J Cell Mol Med， 2015， 19(10): 2469-2480.〖ZK)〗
|
| [55] |
YAN Q， GAO K， CHI Y， et al. NADPH oxidase-mediated upregulation of connexin43 contributes to podocyte injury[J]. Free Radic Biol Med， 2012， 53(6): 1286-1297.〖ZK)〗
|
| [56] |
LIU HF， LIU H， LV LL， et al. CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro[J]. Acta Pharmacol Sin， 2017: 28858296.〖ZK)〗
|
| [57] |
SHI J， LI Q， SHENG M， et al. The role of TLR4 in M1 Macrophage-Induced Epithelial-Mesenchymal transition of peritoneal mesothelial cells[J]. Cell Physiol Biochem， 2016， 40(6): 1538-1548.〖ZK)〗
|
| [58] |
ZHANG L， LI Z， HE W， et al. Effects of astragaloside Ⅳ against the TGF-β1-Induced Epithelial-to-Mesenchymal transition in peritoneal mesothelial cells by promoting Smad 7 expression[J]. Cell Physiol Biochem， 2015， 37(1): 43-54.〖ZK)〗
|
| [59] |
Li ZH，Zhang L，He WM，et al. Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemo attractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis [J]. J Int Mol Sci，2014，15：12959.〖ZK)〗
|
百度学术
下载:
